Skip to main content
. 2014 Nov;52(11):3996–4002. doi: 10.1128/JCM.01962-14

TABLE 3.

hrHPV positivity rate by EIA and LMNX in relation to clinical outcome, i.e., among women who had histologically confirmed high-grade disease (CIN2+ or CIN3+) in the follow-up and women who had normal cytology in the current and the previous screening round (<CIN1)a

Study population and age group CIN2+
 CIN3+
 <CIN1
EIA positive
 LMNX positiveb
 EIA positive
 LMNX positiveb
 EIA positive
 LMNX positiveb
% n/N % n/N % n/N % n/N % n/N % n/N
Screening populationc 100 13/13 100 13/13 100 8/8 100 8/8 9.7 72/746 9.5 69/746
    ≥30 yrs 100 5/5 100 5/5 100 2/2 100 2/2 7.6 48/633 7.4 47/633
    <30 yrs 100 8/8 100 8/8 100 6/6 100 6/6 21.2 24/113 19.5 22/113
Enriched populationd 93.3 83/89 95.5 85/89 97.9 46/47 97.9 46/47 n/a n/a n/a n/a
    ≥30 yrs 92.3 36/39 94.9 37/39 95.5 21/22 95.5 21/22 n/a n/a n/a n/a
    <30 yrs 94.0 47/50 96.0 48/50 100 25/25 100 25/25 n/a n/a n/a n/a
Overall population 94.1 96/102 96.1 98/102 98.2 54/55 98.2 54/55 9.7 72/746 9.2 69/746
    ≥30 yrs 93.2 41/44 95.5 42/44 95.8 23/24 95.8 23/24 7.6 48/633 7.4 47/633
    <30 yrs 94.8 55/58 96.6 56/58 100 31/31 100 31/31 21.2 24/113 19.5 22/113
a

Positivity rates are stratified by population (screening, enriched, or overall) and subsequently by age group (women 30 years and older or women younger than 30 years old). <CIN1, women who had normal cytology during the current as well as the previous screening round 3 years earlier; CIN2+, women diagnosed with CIN2, CIN3, or invasive squamous carcinoma within 18 months of follow-up; CIN3+, women diagnosed with CIN3 or invasive squamous carcinoma within 18 months of follow-up; n/N, number of women with the indicated disease characteristics and test result/total number of women; n/a, not applicable.

b

A positive LMNX result represents detection of one or more of the following 14 HPV genotypes: HPV16, HPV18, HPV31, HPV33, HPV35, HPV39, HPV45, HPV51, HPV52, HPV56, HPV58, and HPV59 (12 HPVs classified by IARC as carcinogenic; class 1) and, additionally, HPV68 (class 2A) and HPV66 (class 2B).

c

Screening population: a study population of women consecutively attending a cervical cancer screening program.

d

Enriched population: a study population of women referred for abnormal cytology.